Tags

Type your tag names separated by a space and hit enter

Neuroprotective and neurotoxic roles of levodopa (L-DOPA) in neurodegenerative disorders relating to Parkinson's disease.
Amino Acids. 2002; 23(1-3):57-63.AA

Abstract

Despite its being the most efficacious drug for symptom reversal in Parkinson's disease (PD), there is concern that chronic levodopa (L-DOPA) treatment may be detrimental. In this paper we review the potential for L-DOPA to 1). autoxidize from a catechol to a quinone, and 2). generate other reactive oxygen species (ROS). Overt toxicity and neuroprotective effects of L-DOPA, both in vivo and in vitro, are described in the context of whether L-DOPA may accelerate or delay progression of human Parkinson's disease.

Authors+Show Affiliations

Department of Pharmacology, Quillen College of Medicine, East Tennessee State University, Johnson City, Tennessee 37614, USA. kostrzewa@etsu.eduNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, U.S. Gov't, P.H.S.
Review

Language

eng

PubMed ID

12373519

Citation

Kostrzewa, R M., et al. "Neuroprotective and Neurotoxic Roles of Levodopa (L-DOPA) in Neurodegenerative Disorders Relating to Parkinson's Disease." Amino Acids, vol. 23, no. 1-3, 2002, pp. 57-63.
Kostrzewa RM, Kostrzewa JP, Brus R. Neuroprotective and neurotoxic roles of levodopa (L-DOPA) in neurodegenerative disorders relating to Parkinson's disease. Amino Acids. 2002;23(1-3):57-63.
Kostrzewa, R. M., Kostrzewa, J. P., & Brus, R. (2002). Neuroprotective and neurotoxic roles of levodopa (L-DOPA) in neurodegenerative disorders relating to Parkinson's disease. Amino Acids, 23(1-3), 57-63.
Kostrzewa RM, Kostrzewa JP, Brus R. Neuroprotective and Neurotoxic Roles of Levodopa (L-DOPA) in Neurodegenerative Disorders Relating to Parkinson's Disease. Amino Acids. 2002;23(1-3):57-63. PubMed PMID: 12373519.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Neuroprotective and neurotoxic roles of levodopa (L-DOPA) in neurodegenerative disorders relating to Parkinson's disease. AU - Kostrzewa,R M, AU - Kostrzewa,J P, AU - Brus,R, PY - 2002/10/10/pubmed PY - 2004/2/27/medline PY - 2002/10/10/entrez SP - 57 EP - 63 JF - Amino acids JO - Amino Acids VL - 23 IS - 1-3 N2 - Despite its being the most efficacious drug for symptom reversal in Parkinson's disease (PD), there is concern that chronic levodopa (L-DOPA) treatment may be detrimental. In this paper we review the potential for L-DOPA to 1). autoxidize from a catechol to a quinone, and 2). generate other reactive oxygen species (ROS). Overt toxicity and neuroprotective effects of L-DOPA, both in vivo and in vitro, are described in the context of whether L-DOPA may accelerate or delay progression of human Parkinson's disease. SN - 0939-4451 UR - https://www.unboundmedicine.com/medline/citation/12373519/Neuroprotective_and_neurotoxic_roles_of_levodopa__L_DOPA__in_neurodegenerative_disorders_relating_to_Parkinson's_disease_ L2 - https://dx.doi.org/10.1007/s00726-001-0110-x DB - PRIME DP - Unbound Medicine ER -